Allostera has seven Allosteramers™ in its pipeline with a focus on inflammatory diseases. Allostera has one orally active lead Allosteramer™: APG2305 an IL23R inhibitor for autoimmune diseases.

Allostera also has products in development against other inflammation targets including an oral IL1R inhibitor and an oral TNFR inhibitor.